Document:

Exhibit 10.1 to Vascular Solutions, Inc. Form 8-K dated April 8, 2008

Exhibit 10.1 

 

Execution Form

 

SETTLEMENT AGREEMENT

This Settlement Agreement is entered into as of April 8, 2008, and shall be effective as of the Effective Date defined hereinafter, by and between Diomed Inc. (“Diomed”), a Delaware corporation having a principal place of business at One Dundee Park, Suite 5, P.O. Box 97, Andover, Massachusetts (telecopy 978-475-8488) and Vascular Solutions, Inc. (“VSI”), a Minnesota corporation with a place of business at 6464 Sycamore Court, Minneapolis, Minnesota 55369.  Diomed and VSI are referred to herein individually as a “Party” and collectively as “the Parties.”

W I T N E S S E T H

WHEREAS, prior to the Petition Date, Diomed filed a Complaint against VSI in the United States District Court for the District of Massachusetts (the “Court”), Civil Action No. 04-10444 (consolidated under Civil Action No. 04-10019) (the “Litigation”) alleging infringement of U.S. Patent No. 6,398,777 (“the ‘777 patent”); and

WHEREAS, final judgment (the “Judgment”) in favor of Diomed was entered by the Court on August 3, 2007; and

WHEREAS, VSI filed a notice of appeal (the “Appeal”) to the United States Court of Appeals for the Federal Circuit (“CAFC”); and 

WHEREAS, Hercules Technology Growth Capital Inc. (“HTGC”) claims a security interest and lien in the Judgment; and

WHEREAS, on March 14, 2008 (the “Petition Date”) Diomed and its parent, Diomed Holdings Inc., each respectively filed a voluntary petition for relief under chapter 11 to Title 11 of the United States Code, 11 U.S.C. §§ 101 et seq. (the “Bankruptcy Code”) in the United States 

 

Bankruptcy Court for the District of Massachusetts (Worchester Division) (the “Bankruptcy Court”) at jointly administered Case No. 08-40749 (the “Bankruptcy Case”); and 

WHEREAS, Diomed remains in control of its business and affairs as a debtor-in-possession pursuant to section 1107 and 1108 of the Bankruptcy Code; and

WHEREAS, this Settlement Agreement, subject to approval by the Bankruptcy Court, is entered into for the purpose of settling and compromising the monetary judgment awarded during the Litigation, any post judgment interest thereon, and any claims for costs Diomed might have against VSI; and

WHEREAS, each Party has relied wholly upon its own judgment, after consultation with counsel, in entering into this Settlement Agreement;

WHEREAS, nothing herein is intended nor shall be construed to have any effect on any claims or counterclaims in this Litigation or any other litigation between Diomed and/or VSI and any entity that is not a Party to this Agreement;

NOW, THEREFORE, in consideration of the mutual covenants and undertakings set forth herein, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

1.   On the Effective Date, VSI and Diomed shall send a letter or other required documents to Wells Fargo Insurance (“Wells Fargo”), surety on the supersedeas bond filed by VSI in connection with the Appeal, informing Wells Fargo that the Parties have entered into this Agreement, and instructing Wells Fargo to immediately take, from the assets deposited by VSI with Wells Fargo as security for the supersedeas bond, the sum of three million five hundred eighty-six thousand four hundred seventy-seven dollars and fifty cents ($3,586,477.50) (the “VSI Payment”) and deliver such sum in escrow to 

 

2

bankruptcy counsel to Diomed, McGuireWoods LLP (the “Escrow Agent”), to be disbursed to Diomed pursuant to the procedures set forth in Paragraphs 2 and 3 of this Agreement.  The Parties agree that all other funds held by Wells Fargo are the sole and exclusive property of VSI and shall be returned to VSI at its direction.  Diomed will execute and shall cause HTGC to execute any documents necessary to waive any claims to all funds held by Wells Fargo in excess of the VSI Payment set forth above and to confirm that all such excess funds shall be returned at VSI’s direction.  In the event that Wells Fargo fails to make the payment described above to the Escrow Agent within three business days of receipt of the documents requesting such payment, VSI shall, by close of business on the very next business day, make the $3,586,477.50 payment by wire transfer in
immediately available funds to the Escrow Agent in lieu of the payment from Wells Fargo.  As a condition to such payment by VSI, Diomed will deliver to Wells Fargo and cause HTGC to deliver to Wells Fargo any documents required relinquishing and waiving any claim to the funds held by Wells Fargo and confirming that such funds shall be released as directed by VSI.

2.   On the next business day after the VSI Payment has been placed in escrow with the Escrow Agent, the Parties shall submit, or cause to be submitted, a joint request to the CAFC that the CAFC dismiss the Appeal pursuant to Fed. R. App. P. 42.  The joint request (the “Joint Request”) shall be substantially in the form of Exhibit A to this Agreement.  

3.   Within two (2) business days after the CAFC dismisses the Appeal pursuant to the Joint Request, Diomed shall execute and deliver to the Escrow Agent and cause the 

 

3

Escrow Agent to provide to VSI a Satisfaction of Judgment (the “Satisfaction of Judgment”) which shall provide that VSI has satisfied in full the monetary judgment of the Court entered on August 3, 2007 and is therefore released from said monetary obligation.  The Satisfaction of Judgment shall be substantially in the form of Exhibit B to this Agreement.  The Satisfaction of Judgment shall be delivered with a written release from HTGC of its security interest and lien in the Judgment (the “Secured Creditor Release”).  The Secured Creditor Release shall be substantially in the form of Exhibit C to this Agreement.  After delivery of the Satisfaction of Judgment and the Secured Creditor Release to VSI, the Escrow Agent will be permitted to disburse the VSI Payment
in the amount set forth in the Order of the Bankruptcy Court authorizing and approving this Agreement.  Diomed further agrees that, in light of this Agreement and the payment it is receiving, Diomed is not entitled to recover any costs from VSI relating to the Litigation and agrees not to file a Bill of Costs as to VSI in either the Court or CAFC.  In addition, Diomed will, and will cause HTGC to, execute any necessary documents to effectuate the formal release of the supersedeas bond provided by VSI in connection with the Appeal.  Nothing herein or in the Satisfaction of Judgment shall amend, alter, or release VSI’s obligations pursuant to the Permanent Injunction entered by the Court on July 2, 2007. 

4.   This Agreement shall be binding upon each Party, its parents, subsidiaries, affiliates, partners, shareholders, agents, employees, representatives, successors and assigns.

5.   For a period commencing on the Effective Date and running for one hundred eighty (180) days thereafter, neither Party shall commence any new civil action against the 

 

4

other Party or its parent or subsidiary entities, on any basis for any alleged cause of action, whether or not now known, arising from any facts or circumstances having taken place prior to the date hereof.  In the event of any new civil action or reexamination involving the '777 patent, or any reissued or reexamined version thereof, or any foreign counterpart thereto, neither Party shall be precluded from raising or litigating any issue that was or could have been raised in the Litigation and neither Party shall claim that collateral estoppel, res judicata or any other legal doctrine precludes any such issue from being raised and litigated.  Furthermore, no appeal shall be taken from the Order of the Court dated January 15, 2008 pertaining to allegations of contempt.

6.   The Effective Date of this Agreement shall be the date upon which all of the following have occurred: 

(a)   approval and authorization of this Agreement by the Board of Directors of Diomed, with notice given by Diomed to VSI; and 

(b)   approval and authorization of this Agreement by the Board of Directors of VSI, with notice given by VSI to Diomed; and

(c)   entry of an order by the Bankruptcy Court in a form and substance satisfactory to VSI authorizing and approving this Agreement in accordance with Federal Rule of Bankruptcy Procedure 9019 and Bankruptcy Code Section 363.

 

If the Effective Date has not occurred by April 18, 2008, then either Diomed or VSI shall have the right to terminate this Agreement by written notice to the other.  Notwithstanding the foregoing, Diomed shall use good faith best efforts to have the Bankruptcy Court consider authorization and approval of the Agreement on its previously scheduled hearing date of April 16, 2008.

7.   With respect to the owners of any right, title, or interest in or to the ‘777 patent or any foreign counterparts thereto, subject to receipt of the approval of its Board of 

 

5

Directors referred to in Section 6(a), Diomed hereby represents and warrants that it has full authority on behalf of all owners to enter into this Agreement as provided by Paragraph 4.6(b) of the July 11, 2003 License Agreement between Diomed and Endolaser Associates LLC (which is the only entity that has any such rights other than Diomed) and to perform its obligations under this Agreement.  With respect to inventor and former owner Dr. Robert Min, Diomed represents and warrants that it has full authority to enter into this Agreement as provided by Paragraph 5.4(b) of the July 23, 2003 Purchase Agreement between Diomed and Dr. Min, and to perform its obligations under this Agreement.  

8.   Subject to receipt of the approval of its Board of Directors referred to in Section 6(b), VSI hereby represents and warrants that it has full authority to enter into this Agreement and to perform its obligations under this Agreement.  

9.   This Agreement shall be governed by and be interpreted under the internal laws of the Commonwealth of Massachusetts, without regard to conflicts of laws principles, and the Parties consent to personal jurisdiction in Massachusetts and agree that all litigation to enforce the terms hereof shall occur in a court of competent jurisdiction within the federal or state courts of Massachusetts.

10. Should any provision of this Agreement be declared or be determined by any court to be illegal or invalid, the validity of the remaining parts, terms, or provisions shall not be affected thereby and the illegal or invalid part, term, or provision shall be deemed not to be part of this Agreement.

 

6

11. Both Parties having contributed to the drafting of this Agreement, there shall be no presumption against either Party in the interpretation of any ambiguities it may contain. 

12. This Agreement supersedes any prior or contemporaneous communications, whether written or oral, concerning the terms of this settlement, and it constitutes the full and complete agreement of the Parties.  This Agreement shall not be orally modified in any respect, and can be modified only by the written agreement of both Parties.

13. All notices, requests and demands to or upon the Parties to be effective shall be in writing (including by telecopy), and, unless otherwise expressly provided herein, shall be deemed to have been duly given or made when delivered, or one business day after being deposited in the mail, postage prepaid, or, in the case of telecopy notice, when received, sent to the address set forth in the first paragraph of this Agreement (or to such other address as may be hereafter notified by any Party). 

14. This Agreement may be executed in counterparts and/or by facsimile.  Any Party that provides its signature by facsimile shall provide the opposing Party with an original ink signature within five business days thereafter; however, this Agreement shall take full effect immediately upon the exchange of the Parties’ signatures by facsimile.

15. Each person signing this Agreement represents that he is authorized to sign it on behalf of the Party for which he purports to sign.   

[Signature page follows.]

 

7

IN WITNESS WHEREOF, each of the Parties has caused this Agreement to be executed on its behalf by the signature of its officer affixed below.

	
            DIOMED, INC.
 	
             
 	
            VASCULAR SOLUTIONS, INC.
 
	 
	
            By:    
 	
            /s/ David Swank
 	
             
 	
            By:   
 	
            /s/ Howard Root
 
	 
	
            Name:   
 	
            David Swank
 	
             
 	
            Name:   
 	
            Howard Root
 
	 
	
            Title:   
 	
            CFO
 	
             
 	
            Title:   
 	
            CEO
 
	 
	
            Dated:   April 8, 2008
 	
             
 	
            Dated:   April 8, 2008
 

 

 

 

8

Exhibit 10.1 

 

EXHIBITS TO SETTLEMENT AGREEMENT

Exhibit 10.1 

 

EXHIBIT A

 

Joint Request to United States Court of Appeals for the Federal Circuit

for Dismissal of Appeal by Vascular Solutions, Inc.

 

 

Exhibit 10.1 

 

UNITED STATES COURT OF APPEALS

FOR THE FEDERAL CIRCUIT

 

	
            Diomed, Incorporated,
 	
            )
 
	
             
 	
            )
 
	
            Plaintiff/Appellee
 	
            )
 
	
             
 	
            )
 
	
            v.
 	
            )
 	
            Docket No. 2007-1474
 
	
             
 	
            )
 
	
            Vascular Solutions, Inc.
 	
            )
 
	
             
 	
            )
 
	
            Defendant/Appellant
 	
            )
 

 

 

STIPULATION DISMISSING APPEAL

 

Pursuant to Rule 42(b) of the Federal Rules of Appellate Procedure, the parties to this appeal, Vascular Solutions, Inc. (defendant-appellant) and Diomed, Incorporated (plaintiff/appellee), hereby agree to dismiss the appeal, without costs or attorney’s fees to either party.

	
            Dated: April __, 2008
 	
             
 	
            Dated:  April __, 2008
 
	 
	 
	 
	
             
 	
             
 	
             
 
	
            Attorney for Appellant
 	
             
 	
            Attorney for Appellee
 
	
            Vascular Solutions, Inc.
 	
             
 	
            Diomed, Incorporated
 
	 
	
            Heather D. Redmond
 	
             
 	
            Michael A. Albert
 
	
            Dorsey & Whitney LLP
 	
             
 	
            Wolf, Greenfield & Sacks, P.C.
 
	
            50 South Sixth Street
 	
             
 	
            600 Atlantic Avenue
 
	
            Minneapolis, MN 55402-1498
 	
             
 	
            Boston, MA 02210-2206
 
	
            612-340-2600
 	
             
 	
            617-646-8000
 
	 
	
            SO ORDERED:
	
             

	 
	 
	 
	
             
 	
             
 	
             
 

PROOF OF SERVICE

 

This is to certify that a copy of the foregoing was sent by mail this ___ day of April, 2008, to:

 

Michael A. Albert

Michael N. Rader

Charles T. Steenburg

Wolf, Greenfield & Sacks, P.C.

600 Atlantic Avenue

Boston, MA 02210-2206

617-646-8000

 

 

	
             
 	
             
 

	
             
 	
            Heather D. Redmond
 

 

 

 

 

2

Exhibit 10.1 

 

 

EXHIBIT B

 

Satisfaction of Judgment

 

Exhibit 10.1 

 

IN THE UNITED STATES DISTRICT COURT

FOR THE DISTRICT OF MASSACHUSETTS

 

	
             

DIOMED, INC.,

 

Plaintiff,

 

v.

 

ANGIODYNAMICS, INC.,

 

Defendant.
 	
             

 

 

 

 

Civil Action No. 04-10019 NMG
 
	
             

DIOMED, INC.,

 

Plaintiff,

 

v.

 

VASCULAR SOLUTIONS, INC.

 

Defendant.
 	
             

 

 

 

 

Civil Action No. 04-10444 NMG

(CONSOLIDATED UNDER

04-10019 NMG)
 

 

SATISFACTION OF JUDGMENT AGAINST VASCULAR SOLUTIONS, INC.

 

A judgment was entered in the above action on August 3, 2007 in favor of Diomed, Inc. and against Vascular Solutions, Inc. in the amount of $4,975,000 plus interest from March 30, 2007.  This judgment, with interest, has been satisfied, and it is certified that there are no outstanding executions with any Sheriff of Marshall.

Therefore, full and complete satisfaction of this judgment against Vascular Solutions, Inc. is acknowledged, and the Clerk of the Court is authorized and requested to make an entry pursuant to Local Rule 58.2(a)(2) of the full and complete satisfaction of the judgment against Vascular Solutions, Inc.

This document shall not be construed as a satisfaction of, or otherwise to affect in any way, the judgment that the Court entered on August 3, 2007 in favor of Diomed, Inc. and against 

 

AngioDynamics, Inc. in the amount of $9,710,000 plus interest from March 30, 2007.  In addition, this document shall not be construed to have any affect on the Permanent Injunction entered by the Court on July 2, 2007 (D.I. 287), which remains in full force and effect.

 

	
             
 	
            Respectfully Submitted,
 
	 
	
             
 	
            DIOMED, INC.
 
	
             
 	
            By its attorneys,
 
	
            Dated:  April ___, 2008
 	
             
 
	
             
 	
            Michael A. Albert (BBO #558566)
 
	
             
 	
            Malbert@wolfgreenfield.com
 
	
             
 	
            Michael N. Rader (BBO #646990)
 
	
             
 	
            mrader@wolfgreenfield.com
 
	
             
 	
            John L. Strand (BBO #654985)
 
	
             
 	
            jstrand@wolfgreenfield.com
 
	
             
 	
            WOLF, GREENFIELD & SACKS, P.C.
 
	
             
 	
            600 Atlantic Avenue
 
	
             
 	
            Boston, MA 02210
 
	
             
 	
            (617) 646-8000
 

 

 

CERTFICATE OF SERVICE

 

I certify that this document is being filed through the Court’s electronic filing system, which serves counsel for other parties who are registered participants as identified on the Notice of Electronic Filing (NEF).  Any counsel for other parties who are not registered participants are being served by first class mail on the date of electronic filing.

 

	
             
 	
            /s/ Michael A. Albert
 

 

 

 

2

Exhibit 10.1 

 

EXHIBIT C

 

Secured Creditor Release

 

 

 

 

PARTIAL RELEASE OF SECURITY INTEREST IN JUDGMENT

KNOW ALL MEN BY THESE PRESENTS, that HERCULES TECHNOLOGY GROWTH CAPITAL, INC. (hereinafter referred to as “Secured Party”), DOES HEREBY CERTIFY, on behalf of itself, its successors, legal representatives and assigns, that all security interests it holds in the judgment listed on Schedule A attached hereto (the “Judgment”) in favor of DIOMED, INC. and DIOMED HOLDINGS, INC., each a Delaware corporation (collectively, the “Debtors”), are hereby released solely as it relates to Vascular Solutions, Inc. (“VSI”), and all right, title and interest in the Judgment as it relates solely to VSI, previously granted to Secured Party are hereby reassigned to Debtors, without recourse or representation or warranty, express or implied, of any kind.  This Partial Release is limited to the Judgment listed on the attached Schedule A only as it relates specifically to
VSI, and does not constitute a release of any security interests of Secured Party in other assets of the Debtors, including without limitation the Judgment and related rights as it relates to AngioDynamics, Inc. or any other party, all of which security interests shall remain in full force and effect.

The undersigned agrees that it will execute and deliver to Debtors any and all further documents or instruments and do any and all further acts which Debtors (or Debtors’ agent or designees) reasonably request to effectuate the intention of this Partial Release of Security Interest in Judgment, in each case at the sole cost and expense of Debtors and their affiliates.

IN WITNESS WHEREOF, Secured Party has caused this Partial Release of Security Interest in Judgment to be executed by its duly authorized corporate officer this ______ day of April, 2008.

 

	
             
 	
            HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

	 
	
             
 	
            By:
 	
             
 
	
             
 	
            Name:   
 	
             
 
	
             
 	
            Title:
 	
             
 

 

 

Exhibit 10.1 

 

SCHEDULE A

TO

PARTIAL RELEASE OF SECURITY INTEREST IN JUDGMENT

 

Any judgment of the United States District Court for the District of Massachusetts or any successor court in respect of the litigation relating to the Debtor’s patent infringement case solely against Vascular Solutions, Inc. relating to the ‘777 patent, Civil Action No. 04-10444NMG and Civil Action No. 04-10019NMG, filed with the United States District Court for the District of Massachusetts.exv4w2

 

Exhibit
4.2

AVANIR PHARMACEUTICALS

AMENDMENT NO. 1 TO RIGHTS AGREEMENT

     This Amendment No. 1 (the “Amendment”) to the Rights Agreement, dated as of March 5, 1999 (the
“Rights Agreement”) is entered into as of April 4, 2008, by and between Avanir Pharmaceuticals, a
California corporation (the “Company”), and American Stock Transfer & Trust Company, a New York
corporation (the “Rights Agent”). Capitalized terms used but not otherwise defined herein shall
have the meanings ascribed to them in the Rights Agreement.

RECITALS

     WHEREAS, pursuant to Section 26 of the Rights Agreement, the Company may, from time to time,
supplement or amend any provision of the Rights Agreement without the approval of any holders of
Rights in order to make any changes or provisions in regard to matters or questions arising under
the Rights Agreement that the Company may deem necessary or desirable;

     WHEREAS, the Company intends to offer shares of its Class A Common Stock (the “Common Stock”)
through Piper Jaffray & Co., as placement agent, certain investors pursuant to subscription
agreements to be entered into with such investors on or about March 26, 2008 (the “Offering”);

     WHEREAS, pursuant to Section 1.1 of the Rights Agreement, any Person who, together with all of
its Affiliates and Associates, shall be a Beneficial Owner of 15% or more of the Common Shares of
the Company then outstanding, shall be deemed an Acquiring Person;

     WHEREAS, the Rights Agreement provides that in the event a Person becomes an Acquiring Person,
holders of Rights shall be entitled to certain rights, as set forth in Section 11.1.2 of the Rights
Agreement;

     WHEREAS, Clarus Ventures (“Clarus”) desires to purchase in the Offering, through one or more
of its Affiliates and/or Associates, a number of shares of Common Stock that would cause Clarus to
become an Acquiring Person upon the completion of the Offering; and

     WHEREAS, the Company desires to amend the Rights Agreement as set forth below in connection
with the purchase by Clarus of Common Stock in the Offering.

AGREEMENT

     NOW, THEREFORE, in consideration of the promises and the mutual agreements herein set forth,
the parties hereby agree as follows:

1. Section 1.1 of the Rights Agreement is hereby amended and restated in its entirety to read as
follows:

“1.1. “Acquiring Person” means any Person (as such term is hereinafter defined) who
or which, together with all Affiliates and Associates (as such terms are hereinafter
defined) of that Person, shall be the Beneficial Owner (as such term is hereinafter
defined) of 15% or more of the Common Shares of the Company then outstanding but
shall not include (i) an Exempt Person (as such term is hereinafter defined), (ii)
if, as of March 15, 1999, any Person is the Beneficial Owner of 15% or more of the
Common Shares outstanding (an “Existing Holder”), such Existing Holder shall not be
or become an “Acquiring Person” unless and until such time as such Existing Holder
shall become

 

the Beneficial Owner of one or more additional Common Shares of the Company (other
than pursuant to a dividend or distribution paid or made by the Company on the
outstanding Common Shares in Common Shares or pursuant to a split or subdivision of
the outstanding Common Shares), unless, upon becoming the Beneficial Owner of such
additional Common Shares, such Existing Holder is not then the Beneficial Owner of
15% or more of the Common Shares then outstanding or (iii) any Grandfathered
Person, unless such Grandfathered Person at any time after the Grandfathered Time
becomes the Beneficial Owner of a percentage of the then outstanding Common Shares
equal to or exceeding the Grandfathered Percentage then applicable to such
Grandfathered Person. Notwithstanding the foregoing, no Person shall become an
“Acquiring Person” as the result of an acquisition of Common Shares by the Company
which, by reducing the number of shares outstanding, increases the proportionate
number of shares beneficially owned by such Person to 15% or more of the Common
Shares of the Company then outstanding; provided, however, that if a Person shall
become the Beneficial Owner of 15% (or, in the case of a Grandfathered Person,
the Grandfathered Percentage then applicable to such Grandfathered Person) or
more of the Common Shares of the Company then outstanding solely by reason of share
purchases by the Company and shall, after such share purchases by the Company,
become the Beneficial Owner of one or more additional Common Shares of the Company)
other than pursuant to a dividend or distribution paid or made by the Company on the
outstanding Common Shares in Common Shares or pursuant to a split or subdivision of
the outstanding Common Shares), then such Person shall be deemed to be an “Acquiring
Person” unless upon becoming the Beneficial Owner of such additional shares of
Common Stock such Person does not beneficially own 15% (or, in the case of a
Grandfathered Person, the Grandfathered Percentage then applicable to such
Grandfathered Person) or more of the shares of Common Stock then outstanding.
Notwithstanding the foregoing, if the Board of Directors of the Company determines
in good faith that a Person who would otherwise be an “Acquiring Person,” as defined
pursuant to the foregoing provisions of this Section 1.1, has become such
inadvertently (including, without limitation, because (A) such Person was unaware
that it beneficially owned a percentage of Common Stock that would otherwise cause
such Person to be an “Acquiring Person” or (B) such Person was aware of the extent
of its Beneficial Ownership of Common Stock but had no actual knowledge of the
consequences of such Beneficial Ownership under this Agreement), and without any
intention of changing or influencing control of the Company, and such Person divests
as promptly as practicable a sufficient number of Common Shares so that such Person
would no longer be an Acquiring Person, as defined pursuant to the foregoing
provisions of this Section 1.1, then such Person shall no be deemed to be or have
become an “Acquiring Person” at any time for any purposes of this Agreement. For
all purposes of this Agreement, any calculation of the number of Common Shares
outstanding at any particular time, including for purposes of determining the
particular percentage of such outstanding Common Shares of which any Person is the
Beneficial Owner, shall be made in accordance with the last sentence of Rule
13d-3(d)(1)(i) of the General Rules and Regulations under the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), as in effect on the date of this
Agreement.”

2. Section 1 of the Rights Agreement is amended by adding at the end of said section the following
definitions:

“1.14 “Grandfathered Percentage” shall initially be 20.40%; provided that in the
event any Grandfathered Person shall sell, transfer, distribute or otherwise dispose
of any outstanding Common Shares after the Grandfathered Time, the Grandfathered
Percentage

 

shall, immediately after such sale, transfer, distribution or disposition, be
adjusted downward, with respect to such Grandfathered Person, to equal the lesser of
(i) the Grandfathered Percentage as in effect immediately prior to such sale,
transfer, distribution or disposition or (ii) the percentage of outstanding Common
Shares that such Grandfathered Person Beneficially Owns immediately following such
sale, transfer or disposition plus an additional 0.50%.

1.42 “Grandfathered Person” shall mean Clarus Ventures and its Affiliates and
Associates including, without limitation, Clarus Lifesciences I, L.P., Clarus
Ventures I, G.P., L.P., and Clarus Ventures I, LLC. Notwithstanding anything to
the contrary provided in this Agreement, any Grandfathered Person who after the
Grandfathered Time becomes the Beneficial Owner of less than 15% of the Common
Shares then outstanding shall thereupon cease to be a Grandfathered Person and shall
thereafter be subject to all of the provisions of this Agreement in the same manner
as any Person who is not and was not a Grandfathered Person.

1.43 “Grandfathered Time” shall mean the closing of the Offering on April 4, 2008.”

3. The first sentence of Section 3.1 of the Rights Agreement is hereby amended and restated in its
entirety to read as follows:

“Until the earlier of (i) the tenth day after the Shares Acquisition Date or (ii) the tenth
Business Day after the date of the commencement of, or first public announcement of the
intent of any Person (other than an Exempt Person) to commence, a tender or exchange offer
the consummation of which would result in any Person (other than an Exempt Person) becoming
the Beneficial Owner of Common Shares aggregating 15% (or, in the case of a
Grandfathered Person, the Grandfathered Percentage then applicable to such Grandfathered
Person) or more of the then outstanding Common Shares of the Company (the earlier of (i)
and (ii) being herein referred to as the “Distribution Date”), (x) the Rights (unless
earlier expired, redeemed or terminated) will be evidenced (subject to the provisions of
Section 3.2) by the certificates for Common Shares registered in the names of the holders
thereof (which certificates for Common Shares shall also be deemed to be Right Certificates)
and not by separate certificates, and (y) the Rights (and the right to receive certificates
therefor) will be transferable only in connection with the transfer of the underlying Common
Shares.”

4. By execution of this Agreement, the Company shall not be deemed to have compromised or waived
any of its rights under the Rights Agreement.

5. Except as expressly modified herein, all terms and conditions of the Rights Agreement shall
continue in full force and effect.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 

     IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed as of
the day and year first above written. This Amendment may be executed in one or more counterparts,
all of which shall be considered one and the same amendment, and each of which shall be deemed to
be an original.

AVANIR PHARMACEUTICALS

	 	 	 	 
	By:	 	/s/
Keith A. Katkin
	Name:	 	Keith A. Katkin
	Title:	 	President and Chief Executive Officer
	 
	AMERICAN STOCK TRANSFER &

TRUST COMPANY, as Rights Agent
	 
	By:	 	/s/
Herbert J. Lemmer
	Name:	 	Herbert J. Lemmer
	Title:	 	Vice President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00140-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00140-of-00352.parquet"}]]